Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alnylam Pharmaceuticals

448.32
-6.0600-1.33%
Volume:345.39K
Turnover:156.40M
Market Cap:58.77B
PE:-181.96
High:458.75
Open:453.37
Low:447.98
Close:454.38
52wk High:469.81
52wk Low:205.87
Shares:131.08M
Float Shares:126.15M
Volume Ratio:0.71
T/O Rate:0.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4638
EPS(LYR):-2.1790
ROE:-257.82%
ROA:-2.63%
PB:234.51
PE(LYR):-205.74

Loading ...

Alnylam Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
Jun 12

European Commission Approves Alnylam's AMVUTTRA® for Treatment of ATTR Amyloidosis with Cardiomyopathy

Reuters
·
Jun 09

US appeals court sides with Moderna on COVID patent claims

Reuters
·
Jun 04

RBC Capital Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

TIPRANKS
·
May 30

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Scientific Advisory Board to Drive RNA Oncology Advancements

Reuters
·
May 28

Alnylam Pharmaceuticals to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Reuters
·
May 28

Alnylam Pharma (ALNY) Receives a Buy from Barclays

TIPRANKS
·
May 27

Alnylam Pharmaceuticals Releases 2024 ESG Report Highlighting Environmental Impact and Health Equity Initiatives

Reuters
·
May 20

TD Cowen Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)

TIPRANKS
·
May 19

U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, UnitedHealth, Wells Fargo

Reuters
·
May 15

Arbutus Biopharma Q1 2025: Revenue Up 20% to $1.8M, Net Loss Widens to $24.5M, EPS at $(0.13)

Reuters
·
May 14

Alnylam Pharmaceuticals Inc. Conducted Annual Meeting of Stockholders

Reuters
·
May 14

Evercore ISI Keeps Their Buy Rating on Alnylam Pharma (ALNY)

TIPRANKS
·
May 07

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

Business Wire
·
May 05

Analyst Estimates: Here's What Brokers Think Of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its First-Quarter Report

Simply Wall St.
·
May 04

Alnylam Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations

Simply Wall St.
·
May 03

Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk

Benzinga
·
May 03

Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y

Zacks
·
May 02

UBS Adjusts Alnylam Pharmaceuticals Price Target to $349 From $331, Maintains Buy Rating

MT Newswires Live
·
May 02

Analysts Have Conflicting Sentiments on These Healthcare Companies: American Well (AMWL), Alnylam Pharma (ALNY) and Teleflex (TFX)

TIPRANKS
·
May 02